Medtech Helitree completed the minority investment in Pathology Asia.

Synopsis

Medtech Helitree, a private equity firm, completed the minority investment in Pathology Asia, a medical technology and diagnosis service provider company. Financial terms were not disclosed.

Principals

target

Pathology Asia Holdings

bidder

Medtech Helitree

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (2)

christopher ting

CEO at PATHOLOGY ASIA HOLDINGS

Manager

target

Deal

n/a

Total Value

sharon lau

Partner at Latham & Watkins

Lawyer

target

Deals

£ 33.07 B

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy